Determining Clinical Study Experiences of Chronic Lymphocytic Leukemia Patients

This research study aims to address the limited understanding of the challenges faced by specific demographic groups of chronic lymphocytic leukemia patients in their participation in clinical trials.

This trial will scrutinize the experiences of patients diagnosed with chronic lymphocytic leukemia as they take part in a separate medical intervention clinical trial. The focus will be on tracking the rates of completion and withdrawal among these individuals.

It will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future chronic lymphocytic leukemia patients.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Chronic Lymphocytic Leukemia Chronic Disease Disease Attributes Hematologic Diseases Hemic and Lymphatic Diseases Immune System Diseases Immunoproliferative Disorders Leukemia Leukemia, B-Cell Leukemia, Lymphocytic, Chronic, B-Cell Leukemia, Lymphoid Lymphatic Diseases Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Power Life Sciences

San Francisco, California, 94107, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patient has been diagnosed with chronic lymphocytic leukemia
Patient is a minimum of 18 years or older
Able to comprehend the investigational nature of the protocol and provide informed consent

Exclusion criteria

Pregnant or lactating women
Patients who are currently receiving any other investigational drug
Any mental or medical condition that prevents the patient from giving informed consent or participating in the trial

Treatment and study plan

Primary outcomes

Number of chronic lymphocytic leukemia patients who decide to join in a clinical study

Time frame: 3 months
Rate of patients who remain in an chronic lymphocytic leukemia clinical study to completion

Time frame: 12 months

Study contacts

Contact information is provided by the study sponsor or research team.

Michael B Gill

CONTACT

[email protected]

4159004227

Sponsors and collaborators

Lead sponsor

Power Life Sciences Inc.

Industry

Registry information

Official study title

Exploring Patient Experiences of Individuals Joining Chronic Lymphocytic Leukemia Clinical Trials

Important dates

Study start: 2024
Primary completion: 2025
Study completion: 2026
First posted: Jun 12, 2023
Registry last updated: Jun 12, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting